Nevertheless, the link between MPTP and MAO-B activity spurred the initial use of MAO-B inhibitors (e.g., selegiline, rasagiline) as therapy for people with Parkinson disease (Jenner and Olanow 1996), although the basis of their clinical utility is now thought to be much more complex. Here, MAOB is linked to Parkinson disease.